Literature DB >> 28859438

Pharmacokinetics of once-daily dolutegravir and ritonavir-boosted darunavir in HIV patients: the DUALIS study.

Christoph D Spinner1,2, Tim Kümmerle3, Ivanka Krznaric4, Olaf Degen5, Christiane Schwerdtfeger1,2, Alexander Zink2,6, Eva Wolf7, Hartwig H F Klinker8, Christoph Boesecke2,9.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28859438     DOI: 10.1093/jac/dkx105

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


× No keyword cloud information.
  4 in total

Review 1.  The challenging pathway towards the identification of SARS-CoV-2/COVID-19 therapeutics.

Authors:  Marco Siccardi; Jonathan Schapiro; Giovanni Di Perri; David J Back
Journal:  J Antimicrob Chemother       Date:  2020-09-01       Impact factor: 5.790

2.  Adequate plasma levels of dolutegravir in combination with ritonavir-boosted darunavir: a pharmacokinetic subgroup analysis of the DUALIS study.

Authors:  Simon Weidlich; Christoph Boesecke; Jochen Schneider; Hartwig H F Klinker; Alexander Zink; Annamaria Balogh; Eva Wolf; Helen Bidner; Christoph D Spinner
Journal:  J Antimicrob Chemother       Date:  2020-10-01       Impact factor: 5.790

3.  Virologic outcomes of switching to boosted darunavir plus dolutegravir with respect to history of drug resistance.

Authors:  Eva Wolf; Christoph Boesecke; Annamaria Balogh; Helen Bidner; Christiane Cordes; Hans Heiken; Ivanka Krznaric; Tim Kümmerle; Hans-Jürgen Stellbrink; Jochen Schneider; Christoph D Spinner
Journal:  AIDS Res Ther       Date:  2021-09-08       Impact factor: 2.250

4.  Effectiveness, Safety, and Tolerability of a Switch to Dual Therapy with Dolutegravir Plus Cobicistat-Boosted Darunavir in Treatment-Experienced Patients with Human Immunodeficiency Virus.

Authors:  Sang Ah Lee; Shin Woo Kim; Hyun Ha Chang; Hyejin Jung; Yoonjung Kim; Soyoon Hwang; Sujeong Kim; Han Ki Park; Jong Myung Lee
Journal:  Infect Chemother       Date:  2018-09
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.